Skip to content

US · IRTC · MEDICAL - DEVICES

iRhythm Technologies, Inc. (IRTC) intrinsic value and stock valuation

$94.72as of 2026-11-21 · Mkt cap 4.09B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

iRhythm Technologies, Inc. DCF and intrinsic value

InvestorsCraft values IRTC with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from IRTC’s statements →

iRhythm Technologies, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices San Francisco, CA 94103 irhythmtech.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$747.1M+23% 5y CAGRd
20132025
Net income
-$-44.55M
20132025
Free cash flow
$34.5M
20132025
Total equity
$152.8M-14.9% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$747.1M$591.8M$492.7M$410.9M$322.8M
Operating income-$-36.81M-$-115.5M-$-125.16M-$-113.78M-$-99.94M
Net income-$-44.55M-$-113.29M-$-123.41M-$-116.16M-$-101.36M
EPSd-$-1.39M-$-3.63M-$-4.04M-$-3.88M-$-3.46M
Operating cash flow$80.9M$3.39M-$-50.1M-$-23.01M-$-37.75M
Capital expenditure-$-46.34M-$-33.94M-$-40.42M-$-29.83M-$-28.07M
Free cash flow$34.5M-$-30.55M-$-90.53M-$-52.84M-$-65.82M
Total assets$1.02B$931.5M$433.1M$448.2M$463M
Total debt$731.2M$736.9M$129.8M$131M$117.7M
Net debt$495.2M$317.3M$93.7M$52.2M-$-9.85M
Total equity$152.8M$90.9M$210.1M$239.8M$279.5M
Cash and short-term investments$583.8M$535.6M$133.8M$213.1M$239.1M
Income statement
20252024202320222021
Revenue$747.1M$591.8M$492.7M$410.9M$322.8M
Cost of revenue$219.9M$184.3M$160.9M$129.3M$109.3M
Gross profit$527.3M$407.5M$331.8M$281.6M$213.6M
Research and development expenses$84.6M$103.8M$60.2M$46.6M$38.7M
Selling, general and administrative expenses$479.5M$418.6M$385.6M$322.2M$274.8M
Other expenses$0.00$640K$11.1M$26.6M$0.00
Operating expenses$564.1M$523M$457M$395.4M$313.5M
Cost and expenses$784M$707.3M$617.8M$524.7M$422.8M
Interest income$21.5M$21.9M$6.16M$2.35M$120K
Interest expense$13.2M$12.8M$3.65M$4.14M$1.17M
Depreciation and amortization$26.5M$25.8M$22.1M$19.6M$16.6M
Ebitda-$-3.96M-$-74.13M-$-96.86M-$-92.14M-$-83.23M
Operating income-$-36.81M-$-115.5M-$-125.16M-$-113.78M-$-99.94M
Total other income/expenses, net-$-6.79M$2.78M$2.5M-$-2.1M-$-1.05M
Income before tax-$-43.6M-$-112.72M-$-122.66M-$-115.89M-$-100.99M
Income tax expense$950K$560K$750K$270K$370K
Net income-$-44.55M-$-113.29M-$-123.41M-$-116.16M-$-101.36M
Weighted average shares outstanding$32M$31.2M$30.5M$29.9M$29.3M
Weighted average diluted shares outstanding$32M$31.2M$30.5M$29.9M$29.3M
Balance sheet
20252024202320222021
Cash and short-term investments$583.8M$535.6M$133.8M$213.1M$239.1M
Net receivables$75.7M$79.9M$61.5M$49.9M$46.4M
Inventory$21.6M$14M$14M$15.2M$10.3M
Total current assets$702.8M$645.8M$230.8M$288.8M$305.5M
Property, plant and equipment, net$193.4M$172.7M$153.4M$136.3M$140.5M
Goodwill and intangible assets$860K$860K$860K$860K$860K
Long-term investments$69.9M$61.9M$3M$0.00$0.00
Total non-current assets$317.3M$285.6M$202.3M$159.5M$157.4M
Total assets$1.02B$931.5M$433.1M$448.2M$463M
Accounts payable$2.26M$7.22M$5.54M$7.52M$10.5M
Short-term debt$16.7M$15.9M$15.2M$13M$22.8M
Deferred revenue$4.2M$2.93M$3.31M$3.05M$3.05M
Total current liabilities$151.9M$110.9M$107.4M$89.1M$87.9M
Long-term debt$714.5M$721M$114.7M$118M$94.9M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$715.4M$729.6M$115.7M$119.3M$95.6M
Capital lease obligations$81.7M$90.5M$94.9M$96.1M$96.4M
Total liabilities$867.3M$840.5M$223.1M$208.4M$183.5M
Common stock$30K$30K$30K$30K$30K
Retained earnings-$-803.45M-$-758.89M-$-645.61M-$-522.2M-$-406.05M
Accumulated other comprehensive income (loss)$400K$170K-$-110K-$-400K-$-60K
Total equity$152.8M$90.9M$210.1M$239.8M$279.5M
Total investments$417.7M$177.9M$100.6M$134.3M$111.6M
Total debt$731.2M$736.9M$129.8M$131M$117.7M
Net debt$495.2M$317.3M$93.7M$52.2M-$-9.85M
Cash flow statement
20252024202320222021
Net income-$-44.55M-$-113.29M-$-123.41M-$-116.16M-$-101.36M
Depreciation and amortization$26.5M$25.8M$22.1M$19.6M$16.6M
Stock-based compensation$88.3M$76M$77.2M$57.7M$54.5M
Change in working capital-$-91.7M-$-99.12M-$-102.05M-$-65.51M-$-46.23M
Accounts receivable-$-95.43M-$-91.92M-$-81.19M-$-61.84M-$-53.57M
Inventory-$-8.51M-$-220K$980K-$-5.11M-$-4.96M
Accounts payable$28M-$-7.41M-$-1.97M-$-2.99M$6.13M
Net cash provided by operating activities$80.9M$3.39M-$-50.1M-$-23.01M-$-37.75M
Investments in property, plant and equipment-$-46.34M-$-33.94M-$-40.42M-$-29.83M-$-28.07M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-277.06M-$-122.98M-$-1.21M-$-52.43M$105.3M
Common stock issued$12.6M$0.00$0.00$0.00$8.94M
Common stock repurchased$0.00-$-25M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.6M$511.4M$8.82M$26.7M-$-28.58M
Net change in cash-$-183.59M$391.8M-$-42.66M-$-48.73M$38.9M
Cash at end of period$236M$428M$36.2M$78.8M$127.6M
Operating cash flow$80.9M$3.39M-$-50.1M-$-23.01M-$-37.75M
Capital expenditure-$-46.34M-$-33.94M-$-40.42M-$-29.83M-$-28.07M
Free cash flow$34.5M-$-30.55M-$-90.53M-$-52.84M-$-65.82M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About iRhythm Technologies, Inc.

        iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.

        CEO
        Quentin S. Blackford
        Employees
        2.4K
        Beta
        1.27

        Explore

        Frequently asked questions

        What is the intrinsic value of iRhythm Technologies, Inc. (IRTC)?

        iRhythm Technologies, Inc. (IRTC) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IRTC undervalued?

        IRTC trades at a price of $94.72 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.